These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 37882706)
1. Three-Week Versus 4-Week Schedule of nab-Paclitaxel in Patients With Metastatic Breast Cancer: A Randomized Phase II Study. Liu Y; Song G; Di L; Jiang H; Ran R; Zhang R; Zhang Y; Li H Oncologist; 2023 Dec; 28(12):1102-e1302. PubMed ID: 37882706 [TBL] [Abstract][Full Text] [Related]
2. A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial. Gennari A; Sun Z; Hasler-Strub U; Colleoni M; Kennedy MJ; Von Moos R; Cortés J; Vidal MJ; Hennessy B; Walshe J; Parraga KA; Ribi K; Bernhard J; Murillo SM; Pagani O; Barbeaux A; Borstnar S; Rabaglio-Poretti M; Maibach R; Regan MM; Jerusalem G; Ann Oncol; 2018 Mar; 29(3):661-668. PubMed ID: 29228091 [TBL] [Abstract][Full Text] [Related]
3. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N Trials; 2015 Dec; 16():575. PubMed ID: 26673577 [TBL] [Abstract][Full Text] [Related]
4. Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial. Gianni L; Mansutti M; Anton A; Calvo L; Bisagni G; Bermejo B; Semiglazov V; Thill M; Chacon JI; Chan A; Morales S; Alvarez I; Plazaola A; Zambetti M; Redfern AD; Dittrich C; Dent RA; Magazzù D; De Fato R; Valagussa P; Tusquets I JAMA Oncol; 2018 Mar; 4(3):302-308. PubMed ID: 29327055 [TBL] [Abstract][Full Text] [Related]
5. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Untch M; Jackisch C; Schneeweiss A; Conrad B; Aktas B; Denkert C; Eidtmann H; Wiebringhaus H; Kümmel S; Hilfrich J; Warm M; Paepke S; Just M; Hanusch C; Hackmann J; Blohmer JU; Clemens M; Darb-Esfahani S; Schmitt WD; Dan Costa S; Gerber B; Engels K; Nekljudova V; Loibl S; von Minckwitz G; ; Lancet Oncol; 2016 Mar; 17(3):345-356. PubMed ID: 26869049 [TBL] [Abstract][Full Text] [Related]
6. Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer. Tsurutani J; Hara F; Kitada M; Takahashi M; Kikawa Y; Kato H; Sakata E; Naito Y; Hasegawa Y; Saito T; Iwasa T; Taira N; Takashima T; Kashiwabara K; Aihara T; Mukai H Breast; 2021 Feb; 55():63-68. PubMed ID: 33341707 [TBL] [Abstract][Full Text] [Related]
7. Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. Tamura K; Inoue K; Masuda N; Takao S; Kashiwaba M; Tokuda Y; Iwata H; Yamamoto N; Aogi K; Saeki T; Nakayama T; Sato N; Toyama T; Ishida T; Arioka H; Saito M; Ohno S; Yamauchi H; Yamada K; Watanabe J; Ishiguro H; Fujiwara Y Cancer Sci; 2017 May; 108(5):987-994. PubMed ID: 28256066 [TBL] [Abstract][Full Text] [Related]
8. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). Rugo HS; Barry WT; Moreno-Aspitia A; Lyss AP; Cirrincione C; Leung E; Mayer EL; Naughton M; Toppmeyer D; Carey LA; Perez EA; Hudis C; Winer EP J Clin Oncol; 2015 Jul; 33(21):2361-9. PubMed ID: 26056183 [TBL] [Abstract][Full Text] [Related]
9. EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer. Biganzoli L; Cinieri S; Berardi R; Pedersini R; McCartney A; Minisini AM; Caremoli ER; Spazzapan S; Magnolfi E; Brunello A; Risi E; Palumbo R; Leo S; Colleoni M; Donati S; De Placido S; Orlando L; Pistelli M; Parolin V; Mislang A; Becheri D; Puglisi F; Sanna G; Zafarana E; Boni L; Mottino G Breast Cancer Res; 2020 Aug; 22(1):83. PubMed ID: 32758299 [TBL] [Abstract][Full Text] [Related]
10. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life. Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813 [TBL] [Abstract][Full Text] [Related]
11. Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial. Zhao Y; Lv F; Chen S; Wang Z; Zhang J; Zhang S; Cao J; Wang L; Cao E; Wang B; Hu X BMC Cancer; 2018 Oct; 18(1):1019. PubMed ID: 30348118 [TBL] [Abstract][Full Text] [Related]
12. Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases. Xie Y; Gong C; Zhang J; Wang L; Cao J; Tao Z; Li T; Zhao Y; Li Y; Hu S; Wang B; Hu X BMC Cancer; 2021 Nov; 21(1):1174. PubMed ID: 34727875 [TBL] [Abstract][Full Text] [Related]
13. A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer. Ciruelos E; Apellániz-Ruiz M; Cantos B; Martinez-Jáñez N; Bueno-Muiño C; Echarri MJ; Enrech S; Guerra JA; Manso L; Pascual T; Dominguez C; Gonzalo JF; Sanz JL; Rodriguez-Antona C; Sepúlveda JM Oncologist; 2019 Nov; 24(11):e1024-e1033. PubMed ID: 31023863 [TBL] [Abstract][Full Text] [Related]
14. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial. Blohmer JU; Link T; Reinisch M; Just M; Untch M; Stötzer O; Fasching PA; Schneeweiss A; Wimberger P; Seiler S; Huober J; Thill M; Jackisch C; Rhiem K; Solbach C; Hanusch C; Seither F; Denkert C; Engels K; Nekljudova V; Loibl S; JAMA Oncol; 2022 Jul; 8(7):1010-1018. PubMed ID: 35588050 [TBL] [Abstract][Full Text] [Related]
15. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Schmid P; Adams S; Rugo HS; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Hegg R; Im SA; Shaw Wright G; Henschel V; Molinero L; Chui SY; Funke R; Husain A; Winer EP; Loi S; Emens LA; N Engl J Med; 2018 Nov; 379(22):2108-2121. PubMed ID: 30345906 [TBL] [Abstract][Full Text] [Related]
16. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA; Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121 [TBL] [Abstract][Full Text] [Related]
17. A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO). Decker T; Overkamp F; Rösel S; Nusch A; Göhler T; Indorf M; Sahlmann J; Trarbach T BMC Cancer; 2017 Jul; 17(1):499. PubMed ID: 28743247 [TBL] [Abstract][Full Text] [Related]
18. Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib. Symonds L; Linden H; Gadi V; Korde L; Rodler E; Gralow J; Redman M; Baker K; Wu QV; Jenkins I; Kurland B; Garrison M; Smith J; Anderson J; Van Haelst C; ; Specht J Clin Breast Cancer; 2019 Apr; 19(2):e283-e296. PubMed ID: 30737173 [TBL] [Abstract][Full Text] [Related]
19. Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results. Gluz O; Nitz U; Liedtke C; Christgen M; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Bangemann N; Lindner C; Kuemmel S; Clemens M; Potenberg J; Staib P; Kohls A; von Schumann R; Kates R; Kates R; Schumacher J; Wuerstlein R; Kreipe HH; Harbeck N J Natl Cancer Inst; 2018 Jun; 110(6):628-637. PubMed ID: 29228315 [TBL] [Abstract][Full Text] [Related]
20. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial. Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]